星昊医药
(920017)
| 流通市值：24.57亿 | | | 总市值：24.90亿 |
| 流通股本：1.23亿 | | | 总股本：1.25亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 474,999,356.63 | 308,277,810.09 | 142,178,012.19 | 648,042,134.12 |
| 营业收入 | 474,999,356.63 | 308,277,810.09 | 142,178,012.19 | 648,042,134.12 |
| 二、营业总成本 | 393,132,024.11 | 271,151,344.88 | 120,618,943.06 | 560,748,586.74 |
| 营业成本 | 141,743,695.34 | 95,564,552.06 | 45,022,268.47 | 196,656,987.7 |
| 税金及附加 | 5,738,735.78 | 4,166,612.88 | 1,361,609.8 | 9,554,336.77 |
| 销售费用 | 159,498,437.59 | 111,111,893.64 | 48,521,710.02 | 227,469,918.47 |
| 管理费用 | 40,657,504.11 | 26,175,666.06 | 10,869,726.45 | 53,011,257.18 |
| 研发费用 | 52,823,441.16 | 39,475,859.6 | 16,467,401.12 | 77,844,094.79 |
| 财务费用 | -7,329,789.87 | -5,343,239.36 | -1,623,772.8 | -3,788,008.17 |
| 其中:利息费用 | 201,361.11 | 141,305.56 | 70,235 | 256,430.28 |
| 其中:利息收入 | 6,303,234.66 | 4,273,909.8 | 1,237,348.26 | 4,758,072.93 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,110,425.27 | 2,276,969.84 | 1,139,383.56 | 3,860,704.13 |
| 加:投资收益 | 2,913,745.47 | 1,300,088.96 | 717,313.17 | 10,808,052.19 |
| 资产处置收益 | -36.47 | - | - | 0 |
| 资产减值损失(新) | -3,359,273.23 | -3,068,019.01 | -38,435.28 | -385,137.64 |
| 信用减值损失(新) | -2,386,106.46 | -854,202.23 | 331,325.57 | -4,056,918.06 |
| 其他收益 | 15,398,411.25 | 10,021,857.55 | 4,904,033.89 | 21,041,934.42 |
| 四、营业利润 | 96,544,498.35 | 46,803,160.32 | 28,612,690.04 | 118,562,182.42 |
| 加:营业外收入 | 389,666.34 | 85,894.24 | 85,894.24 | 4,060,886.21 |
| 减:营业外支出 | 404,398.19 | 403,675.5 | 50,000 | 31,037,444.94 |
| 五、利润总额 | 96,529,766.5 | 46,485,379.06 | 28,648,584.28 | 91,585,623.69 |
| 减:所得税费用 | 10,276,807.81 | 5,402,123.7 | 3,617,487.37 | 9,952,954.81 |
| 六、净利润 | 86,252,958.69 | 41,083,255.36 | 25,031,096.91 | 81,632,668.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 86,252,958.69 | 41,083,255.36 | 25,031,096.91 | 81,632,668.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 86,252,958.69 | 41,083,255.36 | 25,031,096.91 | 82,882,732.47 |
| 少数股东损益 | - | - | - | -1,250,063.59 |
| 扣除非经常损益后的净利润 | 75,278,307.92 | 36,722,636.36 | 23,170,692.05 | 92,390,810.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.7 | 0.34 | 0.2 | 0.68 |
| (二)稀释每股收益 | 0.7 | 0.34 | 0.2 | 0.68 |
| 八、其他综合收益 | -4,257,248.91 | -4,257,154.95 | 1,020.28 | 1,439,132.92 |
| 归属于母公司股东的其他综合收益 | -4,257,248.91 | -4,257,154.95 | 1,020.28 | 1,439,132.92 |
| 九、综合收益总额 | 81,995,709.78 | 36,826,100.41 | 25,032,117.19 | 83,071,801.8 |
| 归属于母公司股东的综合收益总额 | 81,995,709.78 | 36,826,100.41 | 25,032,117.19 | 84,321,865.39 |
| 归属于少数股东的综合收益总额 | - | 0 | - | -1,250,063.59 |
| 公告日期 | 2025-10-28 | 2025-08-08 | 2025-04-28 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |